Online first
Case report
Published online: 2024-09-24

open access

Page views 93
Article views/downloads 52
Get Citation

Connect on Social Media

Connect on Social Media

Eosinophilic fasciitis in the context of autoimmune skin diseases: a case report

Michał Tabor1, Natalia Mokrzycka1, Natalia Tekiela2, Anna Ruszecka1, Przemysław Borowy3

Abstract

Eosinophilic fasciitis (EF) is a rare autoimmune disorder affecting the connective tissue. It is characterized by painful inflammation and fibrosis, leading to sclerosis of fascia concerning limbs. Diagnosis is mostly based on clinical findings and confirmed by histopathological examination. Its rare occurrence and non-obvious course of this disease, mimicking more common syndromes, often causes diagnostic problems. During the diagnostic process, a number of diseases must be excluded: systemic scleroderma (SS), nephrogenic systemic fibrosis, eosinophilia-myalgia syndrome, or Churg-Strauss syndrome (EGPA). The following case report features a 67-year-old female and identifies the characteristic clinical and laboratory features that allow the differentiation of EF from systemic sclerosis and other autoimmune skin diseases, which is useful in everyday clinical practice. The patient complained of increasing swelling of the lower limbs, forearms, and induration in the subcutaneous tissue without involvement of the hands and feet. Based on the biopsy and additional tests, she was diagnosed with EF and treated primarily with oral glucocorticoids (GC). Due to the present side effects of steroid therapy, the decision was made to reduce the doses of GSs with the introduction of methotrexate (MTX). This modification proved successful, and after 23 weeks of treatment, remission of symptoms was observed without further progression of the disease.

Article available in PDF format

View PDF Download PDF file

References

  1. Niklas K, Niklas A, Puszczewicz M. [Eosinophilic fasciitis]. Postepy Hig Med Dosw (Online). 2015; 69: 488–495.
  2. Wright NA, Mazori DR, Patel M, et al. Epidemiology and Treatment of Eosinophilic Fasciitis: An Analysis of 63 Patients From 3 Tertiary Care Centers. JAMA Dermatol. 2016; 152(1): 97–99.
  3. Stubbs LA, Ogunbona O, Beil E, et al. Juvenile eosinophilic fasciitis: a single center case series. Pediatr Rheumatol Online J. 2024; 22(1): 29.
  4. Al-Ghamdi HS. Vigorous exercise-induced unilateral eosinophilic fasciitis: rare and easily misdiagnosed subtype. Int J Clin Exp Pathol. 2020; 13(7): 1739–1744.
  5. Chittipolu S, Kennard JL, Nahar L. Eosinophilic Fasciitis in a 68-Year-Old Female. Cureus. 2024; 16(2): e53908.
  6. Forouzan P, Riahi RR, Cohen PR. Atorvastatin-induced Lichenoid Drug Eruption: A Case Report and Review of Statin-associated Cutaneous Adverse Events. Cureus. 2020; 12(3): e7155.
  7. Haddad H, Sundaram S, Magro C, et al. Eosinophilic fasciitis as a paraneoplastic syndrome, a case report and review of the literature. Hematol Oncol Stem Cell Ther. 2014; 7(2): 90–92.
  8. Mazilu D, Boltașiu Tătaru LA, Mardale DA, et al. Eosinophilic Fasciitis: Current and Remaining Challenges. Int J Mol Sci. 2023; 24(3).
  9. Das J, Chinoy H, Dick J, et al. A Literature Review of Eosinophilic Fasciitis with an Illustrative Case. Curr Rheumatol Rev. 2017; 13(2): 113–120.
  10. Kumar RR, Kumar U. Groove sign: Heeding clue to eosinophilic fasciitis. Eur J Rheumatol. 2020; 7(1): 52.
  11. Primitivo A, Madeira N, Lopez D, et al. Eosinophilic fasciitis (Shulman disease) with clinical, imaging and pathological correlation. BMJ Case Rep. 2021; 14(12).
  12. Chen Z, Wasti B, Shang Y, et al. Clinical characteristics and risk factors of patients with eosinophilic fasciitis associated with pleural effusion. Sci Rep. 2023; 13(1): 5452.
  13. El Iskandarani S, Khasho M, Merashli M. Tocilizumab in the Treatment of Eosinophilic Fasciitis: A Case Study and Review of Literature. Mediterr J Rheumatol. 2023; 34(1): 78–85.
  14. Dakhode S, Prabhu RM, Barik SK, et al. An Unusual Presentation of a Rare Disease: Eosinophilic Fasciitis. Cureus. 2022; 14(11): e31140.
  15. Wilcox RA. Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2018; 93(11): 1427–1430.
  16. Erez D, Shoenfeld Y, Natour A, et al. Clinical experience with biologic treatment in resistant eosinophilic fasciitis: Case reports and review of the literature. Medicine (Baltimore). 2021; 100(13): e25359.
  17. Mufti A, Kashetsky N, Abduelmula A, et al. Biologic treatment outcomes in refractory eosinophilic fasciitis: A systematic review of published reports. J Am Acad Dermatol. 2022; 86(4): 951–953.
  18. Mazori DR, Kassamali B, Min MS, et al. Characteristics and Outcomes of Eosinophilic Fasciitis-Associated Monoclonal Gammopathy. JAMA Dermatol. 2021; 157(12): 1508–1509.